

TABLE S1. Demographic and Clinical Characteristics and Outcomes of 42 Patients With Treatment-Resistant Depression Treated With Pramipexole

Patient	Age (years)	Sex	Diagnosis ^a	Severity	Impairment	Maximum Dosage of Pramipexole (mg/day)	Outcome	Length of Follow-Up on Pramipexole (months)
1	57	M	MDD	4/5	2/5	5.0	Remission	36
2	54	M	BP-II	4/5	3/5	3.0	Remission	60
3	57	F	MDD	4/5	4/5	3.0	Remission	12
4	67	F	MDD, PD	2/5	2/5	1.5	Remission	12
5	25	M	MDD	4/5	2/5	5.0	Response	6
6	84	M	BP-II	3/5	2/5	2.5	Remission	36
7	41	M	BP-I	2/5	2/5	2.0	Intolerant	<1
8	66	M	BP-II	3/5	3/5	1.0	Nonresponse	3
9	66	F	BP-II (RC)	3/5	3/5	2.0	Remission	12
10	70	F	BPS	2/5	3/5	2.0	Remission	12
11	69	F	BP-I	4/5	4/5	2.0	Remission	24
12	76	M	MDD	3/5	2/5	2.0	Remission	18
13	67	M	MDD	4/5	2/5	1.0	Remission	36
14	54	F	BP-I	3/5	1/5	1.0	Response	18
15	33	F	MDD	3/5	3/5	0.75	Remission	36
16	57	F	BPS	3/5	2/5	1.0	Remission	12
17	58	F	MDD	3/5	2/5	3.0	Intolerant	<1
18	58	F	MDD, PTSD	4/5	4/5	3.0	Response	6
19	65	M	BP-II	2/5	2/5	3.0	Response	12
20	43	M	BP-I	3/5	3/5	2.0	Intolerant	3
21	65	F	BPS	4/5	4/5	3.0	Remission	36
22	47	M	BPS	3/5	3/5	1.0	Intolerant	3
23	42	F	MDD	2/5	2/5	1.5	Remission	6
24	65	M	BP-II	3/5	2/5	3.0	Remission	18
25	45	M	BP-I	3/5	3/5	1.0	Response	12
26	51	M	MDD, GAD	4/5	3/5	2.0	Response	1
27	35	F	MDD, OCD	4/5	4/5	2.5	Response	3
28	73	M	BP-II	4/5	4/5	2.0	Response	1
29	36	F	MDD	4/5	4/5	2.5	Response	12
30	57	M	MDD, MS	4/5	5/5	3.5	Remission	12
31	57	F	MDD	3/5	5/5	3.5	Response	6
32	44	F	MDD	3/5	3/5	0.5	Intolerant	<1
33	43	M	MDD	3/5	4/5	0.5	Intolerant	<1
34	41	F	MDD	4/5	2/5	2.0	Remission	36
35	57	M	BP-II (RC)	4/5	3/5	3.0	Remission	1
36	47	F	BP-I, PTSD	4/5	4/5	3.0	Response	3

continued

TABLE S1, continued

Patient	Age (years)	Sex	Diagnosis ^a	Severity	Impairment	Maximum Dosage of Pramipexole (mg/day)	Outcome	Length of Follow-Up on Pramipexole (months)
37	57	M	MDD/MS/PAs	4/5	4/5	3.75	Remission	7
38	31	F	MDD	3/5	2/5	0.75	Remission	24
39	49	M	MDD	2/5	3/5	0.75	Intolerant ^b	<1
40	44	F	MDD, CPS	4/5	4/5	4.0	Response	6
41	61	M	MDD	4/5	3.5	0.5	Intolerant ^b	<1
42	53	F	MDD, PTSD	4/5	4/5	2.0	Nonresponse	2

^a BP-I, BP-II=bipolar I, bipolar II disorder; BPS=bipolar disorder, specified; CPS=chronic paranoid schizophrenia; GAD=generalized anxiety disorder; MDD=major depressive disorder; MS=multiple sclerosis; OCD=obsessive-compulsive disorder; PAs=panic attacks; PD=panic disorder; PTSD=posttraumatic stress disorder; RC=rapid cycling.

^b Discontinued because of nausea.

TABLE S2. Treatments Prior to Pramipexole in 42 Patients With Treatment-Resistant Depression^a

Patient	Number of Trials									Comments
	SSRI	SNRI	Tricyclic Antidepressant	Bupropion	Monoamine Oxidase Inhibitor	Lithium	Anticonvulsant	Atypical Antipsychotic	ECT	
1	3	1	1	1	1	1	0	1	8	
2	3	0	1	1	1	1	1	1	12	Vagus nerve stimulation therapy added
3	3	1	1	1	0	1	1	1	12	
4	3	2	2	1	0	1	1	1	9	
5	3	2	1	1	1	1	0	1	30–40	
6	2	1	0	1	0	1	1	0	0	
7	3	1	0	1	0	1	1	1	0	
8	3	2	1	1	0	1	2	0	0	
9	3	3	1	0	0	1	2	2	0	Discontinued pramipexole, restarted ^b
10	3	1	1	0	0	0	1	0	0	Relapsed while on pramipexole at 12 months
11	3	1	1	1	0	1	2	0	0	
12	2	1	0	1	0	0	0	0	0	Discontinued pramipexole due to irritability, depression did not return
13	3	1	1	0	0	0	0	0	0	Dopamine abrupt withdrawal syndrome
14	3	1	0	1	0	1	2	1	0	
15	2	1	0	1	0	0	1	0	0	Discontinued pramipexole, restarted ^b
16	2	1	1	1	0	1	0	1	0	Discontinued pramipexole, restarted ^b
17	2	1	1	0	0	0	0	0	0	
18	2	0	1	1	0	0	0	0	0	Prazosin for posttraumatic stress disorder symptoms
19	2	0	0	1	0	1	1	0	0	Discontinued pramipexole, restarted
20	2	2	1	1	0	1	1	1	0	Discontinued pramipexole, restarted
21	3	1	1	1	0	1	1	0	0	
22	3	2	2	1	1	1	4	2	0	
23	3	2	0	1	0	0	0	0	0	Discontinued pramipexole due to pregnancy and became depressed
24	3	2	1	1	0	1	3	2 ^c	0	Pramipexole caused sexual arousal. Perphenazine used as mood stabilizer. Relapsed on pramipexole after 18 months
25	3	1	0	1	0	1	1	2	0	Opioid user
26	2	3	1	1	0	0	0	1 ^c	12	
27	3	1	2	1	0	1	0	1 ^c	14	
28	5	3	1	1	1	1	3	4 ^c	5	Vagus nerve stimulation therapy added

continued

TABLE S2, continued

Patient	Number of Trials									Comments
	SSRI	SNRI	Tricyclic Antidepressant	Bupropion	Monoamine Oxidase Inhibitor	Lithium	Anticonvulsant	Atypical Antipsychotic	ECT	
29	3	1	1	1	0	0	0	0	0	
30	3	2	1	1	1	0	2	0	0	
31	3	2	1	1	0	1	2	0	0	
32	2	2	0	1	0	0	0	1	0	
33	3	2	1	1	0	0	0	1	0	
34	2	2	0	1	0	0	0	0	0	
35	2	2	0	1	1	1	0	1	0	
36	2	1	0	1	1	1	2	2	0	
37	2	2	1	1	0	0	2	2	0	Pregabalin added; low-dosage naltrexone and testosterone added
38	3	2	1	1	0	0	0	0	0	Had panic attacks
39	2	1	1	1	0	0	1	0	0	
40	2	1	0	1	0	0	0	1	0	History of methamphetamine use while on long-acting injection risperidone
41	1	2	2	0	0	0	0	0	0	
42	3	2	2	1	0	0	0	0	0	Stimulants added

^a SNRI=serotonin-norepinephrine reuptake inhibitor; SSRI=selective serotonin reuptake inhibitor.

^b Discontinued for various reasons, became depressed, then once pramipexole was restarted, depression responded again.

^c Aripipizole was used.